Terbium: The Swiss Army Knife of Nuclear Medicine
Terbium is the only element that supplies a clinically useful radionuclide for all four jobs in nuclear medicine: PET imaging, SPECT imaging, alpha therapy and beta therapy. Four blades, one handle. The name comes from the group that characterised the set, at PSI and CERN-MEDICIS — a Swiss Army knife from a Swiss laboratory.
The quadruplet
Four isotopes, one chemistry. Each covers a different role.
| Isotope | Emission | Half-life | Role |
|---|---|---|---|
| 152Tb | β⁺ | ~17.5 h | PET imaging |
| 155Tb | Electron capture; γ ~87 and 105 keV | ~5.3 d | SPECT imaging |
| 149Tb | α (~17%), also β⁺ and electron capture | ~4.1 h | Alpha therapy (and PET-visible) |
| 161Tb | β⁻ with conversion and Auger electrons | ~6.9 d | Beta therapy |
Why one element matters
- Identical chemistry. All four are the same element. The same chelator and the same vector — DOTATATE, PSMA-617, a folate conjugate — label with any of them.
- A true match, not a surrogate. The usual pairing is 68Ga for imaging and 177Lu for therapy. Those are different metals with different ionic radii, so the scan predicts the therapeutic distribution rather than reproducing it.
- Pre-therapy dosimetry. 155Tb SPECT or 152Tb PET can be performed with the same molecule that will later carry 161Tb or 149Tb. The planning study and the treatment differ only in which isotope sits in the chelator.
- Dosimetry. With terbium, what is measured on the scan is what is delivered.
Two isotopes worth knowing separately
- 149Tb. The only lanthanide alpha emitter practical for targeted therapy. Alpha particles deposit their energy over a few cell diameters — high linear energy transfer, lethal to the targeted cell, sparing beyond it.
- 161Tb. On paper it resembles 177Lu: similar half-life, similar beta energy. It differs in emitting far more conversion and Auger electrons, whose range is nanometres to micrometres. That should favour it against micrometastases and single cells, where a beta particle overshoots the target. It also has an imageable gamma, so it can be its own SPECT tracer.
The constraint
- Production. Mass separation or high-energy spallation, not a hospital cyclotron and not a generator.
- 161Tb. The most accessible, made by neutron irradiation of enriched 160Gd, and now in first-in-human work with DOTATOC and PSMA-617.
- 149Tb, 152Tb and 155Tb. Largely research-scale.
- Half-life. 149Tb at about four hours, and 152Tb at under a day, will not travel far from where they are made. Distribution is as much a limit as production.
- A four-blade knife is only useful if you can get hold of one.
Where this fits in practice: Theranostics.
Take home
- One element covers PET, SPECT, alpha therapy and beta therapy.
- Identical coordination chemistry makes the diagnostic scan a true dosimetry surrogate, not an approximation.
- Availability, not physics, is what currently limits it.
Sources
- Müller C, Zhernosekov K, Köster U, et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β⁻ radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. 2012;53(12):1951-9.
- Baum RP, Singh A, Kulkarni HR, et al. First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC. J Nucl Med. 2021;62(10):1391-7.
- Decay data: NNDC / ENSDF evaluated nuclear data for 149Tb, 152Tb, 155Tb and 161Tb.